Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Arvinas Inc [ARVN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 7.55%
SELL
40.00%
return 5.03%
Last Updated31 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

2.79% $ 33.14

BUY 155148 min ago

@ $49.33

Issued: 14 Feb 2024 @ 15:32

Return: -32.81%

Previous signal: Feb 14 - 10:03

Previous signal: Sell

Return: 2.08 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins...

Stats
Today's Volume 950 853
Average Volume 701 101
Market Cap 2.27B
EPS $0 ( 2024-05-29 )
Next earnings date ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.48
ATR14 $0.0470 (0.14%)
Insider Trading
Date Person Action Amount type
2024-05-29 Bain Linda Buy 5 899 Common Stock
2024-05-29 Bain Linda Buy 9 070 Stock Option (right to buy)
2024-05-29 Cunningham Everett Buy 5 899 Common Stock
2024-05-29 Cunningham Everett Buy 9 070 Stock Option (right to buy)
2024-05-29 Kennedy Edward Moore Jr. Buy 5 899 Common Stock
INSIDER POWER
50.57
Last 95 transactions
Buy: 1 604 823 | Sell: 436 779

Volume Correlation

Long: 0.20 (neutral)
Short: -0.90 (strong negative)
Signal:(42.411) Neutral

Arvinas Inc Correlation

10 Most Positive Correlations
OZEM1
DOMO0.928
WSC0.928
RGEN0.912
BMEA0.909
WRAP0.9
BKHAU0.898
BRZE0.894
CRBU0.889
IPA0.888
10 Most Negative Correlations
ARBFX-0.957
FSCHX-0.936
CISS-0.92
AEDFX-0.916
NA-0.915
FDFF-0.904
NVNI-0.901
KCOPX-0.901
INDH-0.899
BUFMX-0.896

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arvinas Inc Correlation - Currency/Commodity

The country flag -0.61
( weak negative )
The country flag -0.56
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.67
( moderate )
The country flag -0.04
( neutral )
The country flag 0.66
( moderate )

Arvinas Inc Financials

Annual 2023
Revenue: $78.50M
Gross Profit: $71.80M (91.46 %)
EPS: $-6.62
FY 2023
Revenue: $78.50M
Gross Profit: $71.80M (91.46 %)
EPS: $-6.62
FY 2022
Revenue: $131.40M
Gross Profit: $123.20M (93.76 %)
EPS: $-5.11
FY 2021
Revenue: $46.00M
Gross Profit: $46.00M (100.00 %)
EPS: $-3.82

Financial Reports:

No articles found.

Arvinas Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Arvinas Inc

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 2.0891840457916 seconds
Number of API calls: 2
Number of DB calls: 8